Engineers Gate Manager LP purchased a new position in shares of Illumina, Inc. (NASDAQ:ILMN) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 18,455 shares of the life sciences company’s stock, valued at approximately $6,774,000. Illumina comprises 0.5% of Engineers Gate Manager LP’s investment portfolio, making the stock its 26th biggest holding.
Other institutional investors also recently added to or reduced their stakes in the company. Janney Montgomery Scott LLC raised its stake in shares of Illumina by 10.0% during the second quarter. Janney Montgomery Scott LLC now owns 23,555 shares of the life sciences company’s stock worth $6,579,000 after purchasing an additional 2,141 shares during the last quarter. Standard Life Aberdeen plc raised its stake in shares of Illumina by 31.1% during the second quarter. Standard Life Aberdeen plc now owns 34,546 shares of the life sciences company’s stock worth $9,650,000 after purchasing an additional 8,199 shares during the last quarter. Waters Parkerson & CO. LLC purchased a new stake in shares of Illumina during the second quarter worth approximately $223,000. Bank of Nova Scotia raised its stake in shares of Illumina by 216.4% during the second quarter. Bank of Nova Scotia now owns 59,185 shares of the life sciences company’s stock worth $16,529,000 after purchasing an additional 40,478 shares during the last quarter. Finally, Eqis Capital Management Inc. raised its stake in shares of Illumina by 40.7% during the second quarter. Eqis Capital Management Inc. now owns 9,676 shares of the life sciences company’s stock worth $2,702,000 after purchasing an additional 2,797 shares during the last quarter. Institutional investors and hedge funds own 89.87% of the company’s stock.
Shares of ILMN stock opened at $328.10 on Friday. Illumina, Inc. has a 1-year low of $203.83 and a 1-year high of $372.61. The firm has a market cap of $45.74 billion, a P/E ratio of 53.28, a price-to-earnings-growth ratio of 2.31 and a beta of 1.08. The company has a current ratio of 2.46, a quick ratio of 2.24 and a debt-to-equity ratio of 0.24.
Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Tuesday, October 23rd. The life sciences company reported $1.52 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.26 by $0.26. The firm had revenue of $853.00 million for the quarter, compared to analyst estimates of $825.65 million. Illumina had a return on equity of 27.10% and a net margin of 21.09%. Illumina’s quarterly revenue was up 19.5% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.11 earnings per share. Equities analysts predict that Illumina, Inc. will post 5.75 EPS for the current fiscal year.
A number of brokerages recently weighed in on ILMN. Zacks Investment Research lowered Illumina from a “buy” rating to a “hold” rating in a report on Wednesday, October 24th. Cowen upped their price objective on Illumina from $275.00 to $315.00 and gave the stock an “outperform” rating in a report on Tuesday, July 10th. Barclays upped their price objective on Illumina from $350.00 to $370.00 and gave the stock an “overweight” rating in a report on Wednesday, October 24th. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $350.00 price objective on shares of Illumina in a report on Tuesday, July 31st. Finally, Canaccord Genuity reaffirmed a “buy” rating and set a $340.00 price objective (up previously from $330.00) on shares of Illumina in a report on Friday, July 27th. Six research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. Illumina has a consensus rating of “Buy” and a consensus price target of $330.94.
In other Illumina news, Director Robert S. Epstein sold 1,346 shares of the company’s stock in a transaction on Friday, September 7th. The stock was sold at an average price of $345.14, for a total value of $464,558.44. Following the sale, the director now owns 7,139 shares of the company’s stock, valued at $2,463,954.46. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Francis A. Desouza sold 2,100 shares of the company’s stock in a transaction on Thursday, November 1st. The shares were sold at an average price of $310.85, for a total value of $652,785.00. Following the completion of the sale, the insider now directly owns 71,935 shares in the company, valued at approximately $22,360,994.75. The disclosure for this sale can be found here. Insiders sold 55,629 shares of company stock worth $18,631,589 in the last three months. 0.54% of the stock is owned by corporate insiders.
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.
Recommended Story: Day Trading
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.